Drug Profile
Ultevursen - ProQR Therapeutics
Alternative Names: QR-421; QR-421a; QRX-421Latest Information Update: 12 Dec 2023
Price :
$50
*
At a glance
- Originator ProQR Therapeutics
- Class Antisense RNA; Eye disorder therapies; Oligonucleotides
- Mechanism of Action RNA interference; USH2A protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Retinitis pigmentosa
- Phase II Usher syndromes
Most Recent Events
- 08 Dec 2023 ProQR completes the divestment of sepofarsen and ultevursen to Laboratoires Théa to continue the development of these programs for patients with LCA10 and Usher syndrome
- 27 Sep 2023 ProQR Therapeutics terminates its agreement with Laboratoires Thea
- 02 Aug 2023 ProQR Therapeutics enters into an agreement to transfer its advanced ophthalmic assets to Laboratoires Thea